Group 1 - Gao Yi Asset recently conducted research on three listed companies, including Muyuan Foods, Zhongmi Holdings, and Taiji Group [1][2][3] - Muyuan Foods has partnered with Element Driven to establish Henan Muyuan Anliang Company, with a synthetic biology project that has commenced production at an annual capacity of 30,000 tons [1] - Zhongmi Holdings holds an 11.11% stake in Chengdu Chuanha Robot and Intelligent Equipment Research Institute, and has technological advantages in the field of sealing components for new energy vehicle batteries [2] - Zhongmi Holdings has won bids for water conservancy projects in Yunnan, marking its first breakthroughs in flow regulation valves with a diameter of DN1000 [2] - Taiji Group has developed "Taiji Acute Support Health" smart body and collaborated on the "Herbal Intelligence Library · Traditional Chinese Medicine Model" with several institutions [3] - Taiji Group's subsidiary, Sichuan Nanchong Pharmaceutical Co., produces pediatric hepatitis granules for clearing heat and dampness, and relieving pain [3] Group 2 - Gao Yi Asset Management is a prominent private equity fund management company in China, known for its strong research capabilities and large management scale [4] - The company focuses on capital markets and aims to provide top-notch research support and resources to outstanding investment managers [4] - The research team consists of over 30 members, including experienced investment managers and award-winning fund managers from leading firms [4]

Group 1 - Mingyuan Investment recently conducted research on two listed companies: Kewang Pharmaceutical and Taiji Group [1] - Kewang Pharmaceutical signed a cooperation intention letter with Peking University Medical Department to establish a joint laboratory for enzyme sources and innovative drugs in 2024 [1] - Taiji Group has developed a smart health product called "Taiji Acute Support Health" and collaborated on a traditional Chinese medicine model with several institutions [1] Group 2 - Mingyuan Investment Management Co., Ltd. was established in 2014 with a registered capital of 10 million yuan and focuses on quantitative investment [2] - The company has a strong team for strategy development and risk management, utilizing advanced data mining and statistical analysis [2] - Mingyuan Investment aims to explore and research quantitative investment strategies suitable for the Chinese capital market, leveraging international experience [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [5][17]. Core Viewpoints - The company's performance in 2024 was significantly impacted by high base effects, social inventory, and tax adjustments, leading to a revenue decline of 20.7% year-on-year, with a net profit drop of 96.8% [2][3]. - Despite the challenges faced in 2024, the company has shown signs of recovery in Q1 2025, with a revenue of 28.3 billion, reflecting a 32.8% year-on-year decrease but an improvement from the previous quarter [2][4]. - The company is implementing a strategic marketing system reform focused on clinical value and market demand, aiming to enhance channel integration and terminal expansion, which is expected to support sales recovery [4][5]. Financial Performance Summary - In 2024, the company achieved a revenue of 123.9 billion, with a gross margin of 39.3% and a net margin of 0.4% [2][3]. - The breakdown of revenue by sector in 2024 shows: - Pharmaceutical industry: 70.4 billion (down 32.3%) - Pharmaceutical commerce: 67.4 billion - Traditional Chinese medicine resources: 10.5 billion - Health and international business: 4.6 billion [3]. - The forecast for 2025 projects revenues of 139.1 billion, with a growth rate of 12%, and net profits of 5.6 billion, reflecting a substantial recovery [5][6]. Earnings Forecast - The earnings forecast for 2025, 2026, and 2027 indicates revenues of 139.1 billion, 155.2 billion, and 174.6 billion respectively, with net profits expected to rise significantly from 5.6 billion in 2025 to 8.8 billion in 2027 [5][6]. - The projected growth rates for net profit are 2001% in 2025, 21% in 2026, and 30% in 2027, indicating a strong recovery trajectory [5][6]. Market Position and Strategy - The company is focusing on innovative marketing strategies to reach younger consumers and enhance brand influence through collaborations with media outlets [4]. - The establishment of a strategic market system centered on clinical value and market demand is expected to drive sales growth and improve overall performance [4][5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company experienced a significant decline in performance in Q1 2025, with total revenue of 2.828 billion yuan, down 32.79% year-on-year, and a net profit attributable to shareholders of 75 million yuan, down 69.8% [8] - Despite the short-term performance pressure, the company is undergoing comprehensive reforms and expects a rebound in performance in 2025 as it gradually digests the high base from the first half of the year [8] - The company has successfully integrated 13 products into various medical guidelines and has focused on brand building and marketing reforms to adapt to market changes [8] Financial Summary - Total revenue forecast for 2023 is 15.623 billion yuan, with a projected decline to 12.386 billion yuan in 2024, followed by a recovery to 14.164 billion yuan in 2025 [1] - The net profit attributable to shareholders is expected to drop significantly from 822.13 million yuan in 2023 to 26.65 million yuan in 2024, before rebounding to 513.46 million yuan in 2025 [1] - The earnings per share (EPS) is projected to be 1.48 yuan in 2023, dropping to 0.05 yuan in 2024, and recovering to 0.92 yuan in 2025 [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's operating performance is under pressure in 2024, with a revenue forecast of 12.39 billion yuan, a year-on-year decrease of 20.72%, and a net profit of 27 million yuan, down 96.76% [4] - The company is optimistic about the potential of marketing reforms to drive business development and maintain a "Buy" rating despite the current challenges [4] - The company has adjusted its profit forecasts for 2025-2027, expecting net profits of 553 million yuan, 622 million yuan, and 700 million yuan respectively [4] Financial Performance Summary - In 2024, the company achieved a revenue of 12.39 billion yuan, with a net profit of 27 million yuan and a gross margin of 39.32% [4][7] - The revenue breakdown shows a significant decline in the pharmaceutical industry segment, with a revenue of 7.04 billion yuan, down 32.25%, while the health and international business segment grew by 39.43% to 461 million yuan [5] - The company's expenses include a sales expense ratio of 26.54%, a management expense ratio of 5.49%, and a research and development expense ratio of 2.26% [4] Marketing and Business Transformation - The company is deepening its marketing reforms, focusing on academic foundations and enhancing marketing collaboration [6] - It aims to improve brand image and reach younger audiences through innovative marketing strategies [6] Financial Projections - The company forecasts revenues of 12.68 billion yuan in 2025, 13.23 billion yuan in 2026, and 14.07 billion yuan in 2027, with corresponding net profits of 553 million yuan, 622 million yuan, and 700 million yuan [7][9] - The projected EPS for 2025, 2026, and 2027 is 0.99 yuan, 1.12 yuan, and 1.26 yuan respectively [4][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's operating performance is under pressure in 2024, with a revenue of 12.39 billion yuan (down 20.72% year-on-year) and a net profit of 27 million yuan (down 96.76% year-on-year). The first quarter of 2025 shows a revenue of 2.83 billion yuan (down 32.79% year-on-year) and a net profit of 75 million yuan (down 69.80% year-on-year). The company is optimistic about the long-term growth potential driven by marketing reforms [4][5] - The company is undergoing a marketing transformation, focusing on academic foundations and enhancing marketing collaboration, which has led to 13 products entering 10 treatment guidelines and 19 expert consensus documents [6] Financial Performance Summary - In 2024, the company achieved a revenue of 123.86 billion yuan, with a gross margin of 39.32% (down 9.28 percentage points) and a net margin of 0.41% (down 5.05 percentage points) [4] - The revenue forecast for 2025-2027 is adjusted to 5.53 billion yuan, 6.22 billion yuan, and 7.00 billion yuan respectively, with corresponding EPS of 0.99 yuan, 1.12 yuan, and 1.26 yuan [4][7] - The company's pharmaceutical industrial revenue in 2024 was 70.38 billion yuan (down 32.25%), while the health and international business revenue grew by 39.43% to 4.61 billion yuan [5] Marketing and Transformation Efforts - The company is deepening its marketing reforms, enhancing brand communication, and targeting younger audiences through various media channels to improve brand image and consumer engagement [6]

证券代码：600129 证券简称：太极集团 公告编号：2025-034 重庆太极实业（集团）股份有限公司 关于聘任副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 4 月 23 日召开了第十届董事会第二十八次会议，审议通过了《关 于聘任公司副总经理的议案》。根据《公司章程》相关规定。经公司 总经理于宗斌先生提名，董事会拟聘任郑洪涛先生为公司副总经理， 任期自本次董事会审议通过之日起至第十届董事会届满时止。 郑洪涛先生的任职资格符合《公司法》《上海证券交易所股票上 市规则》等相关法律法规及《公司章程》的相关要求，不存在受到中 国证监会、上海证券交易所及其他有关部门处罚的情形。 个人简历： 郑洪涛，男，1980 年出生，中共党员，西安建筑科技大学暖通 专业本科，高级工程师。历任中国医药集团武汉医药设计院公用工程 室副主任，中国医药集团联合工程有限公司咨询设计事业部副总经理， 中国医药集团联合工程有限公司公用工程室主任，中国医药集团联合 工程有限公司 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-033 重庆太极实业（集团）股份有限公司 关于受让下属子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●重庆太极实业（集团）股份有限公司（以下简称"公司"或"太 极集团"）拟以非公开协议方式受让控股子公司重庆桐君阁股份有限 公司（以下简称：桐君阁股份）和重庆中药材有限公司（以下简称： 中药材公司）分别持有的重庆中药饮片厂有限公司（以下简称：中药 饮片厂）3.92%、1.96%的股权。 ●本次股权转让均为公司与控股子公司之间进行，不涉及外部股 东，不会导致公司合并报表范围发生变化，不会对公司财务及经营状 况产生不利影响。 ●本次中药饮片厂股权转让事宜已经公司第十届董事会第二十 八次会议审议通过。根据《公司章程》规定，该事项无需提交公司股 东大会审议。 为了整合内部资源，优化股权架构与管理关系。公司拟分别以现 金115万元、58万元的价格受让桐君阁股份和中药材公司分别持有的 1 中药饮片厂3.92%和1.96%股权。 （二）决策与审 ...

1 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》 之《第六号—医药制造》的相关规定，现将公司 2025 年第一季度主要经营数 据披露如下： 一、报告期内分行业经营数据 单位：万元 币种：人民币 | | 主营业务收入 | | | 主营业务成本 | | 增长 | 毛利率% | | 同比增 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 2025 年 | 2024 年 | 增长率% | 2025 年 | 2024 年 | 率% | 2025 年 | 2024 年 | 长百分 | | | 1-3 月 | 1-3 月 | | 1-3 月 | 1-3 月 | | 1-3 月 | 1-3 月 | 点 | | 医药工业 | 146,738.3 | 269,332.36 | -45.52 | 81,830.27 | 94,544.60 | -13.4 | 44.23 | 64.90 | -20.67 | | | 2 | | | | | 5 | | | | | 医药商业 | 161,814.3 | 191,066 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-036 重庆太极实业（集团）股份有限公司 关于召开2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 21 日(星期三)下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 5 月 14 日(星期三)至 5 月 20 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 tjzq@taiji.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 重庆太极实业（集团）股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日发布公司 2025 年第一季度报告，为便于广大投资 者更全面深入地了解公司 2025 年第一季度经营成果、财务状况，公 司计划于 2025 年 5 ...